Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Pfizer Inc. (NYSE:PFE) will release its second quarter earnings report before the opening bell on Tuesday, Aug. 4.

Analysts expect the New York-based company to report quarterly earnings of 68 cents per share, down from 78 cents per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $14.39 billion. It reported $14.65 billion last year, according to Benzinga Pro.

On July 30, Pfizer announced positive topline Phase 3 results for LITFULO in patients with nonsegmental vitiligo.

Shares of Pfizer rose 0.1% to close at $25.03 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

• BMO Capital analyst Evan David Seigerman maintained an Outperform rating and slashed the price target from $34 to $30 on July 13, 2026. This analyst has an accuracy rate of 57%.
• Guggenheim analyst Vamil Divan maintained a Buy rating and cut the price target from $36 to $35 on July 13, 2026. This analyst has an accuracy rate of 78%.
• B of A Securities analyst Jason Gerberry maintained a Neutral rating and cut the price target from $27 to $26 on July 10, 2026. This analyst has an accuracy rate of 69%.
• JP Morgan analyst Chris Scott maintained a Neutral rating and cut the price target from $30 to $28 on July 8, 2026. This analyst has an accuracy rate of 66%.
• Cantor Fitzgerald analyst Carter Gould maintained the stock with a Neutral rating with a price target of $27 on July 6, 2026. This analyst has an accuracy rate of 65%

Considering buying PFE stock? Here’s what analysts think:

Photo via Shutterstock